BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3585663)

  • 1. Amplification of N-myc oncogene in stage II and IVS neuroblastomas may be a prognostic indicator.
    Nakagawara A; Ikeda K; Tsuda T; Higashi K; Okabe T
    J Pediatr Surg; 1987 May; 22(5):415-8. PubMed ID: 3585663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-myc amplification in neuroblastomas: histopathological, DNA ploidy, and clinical variables.
    Oppedal BR; Oien O; Jahnsen T; Brandtzaeg P
    J Clin Pathol; 1989 Nov; 42(11):1148-52. PubMed ID: 2584426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical aspects of N-myc oncogene amplification of neuroblastoma.
    Nakagawara A; Ikeda K; Yokoyama T; Tsuda T; Higashi K
    Surgery; 1988 Jul; 104(1):34-40. PubMed ID: 3388178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-myc amplification in an infant with stage IVS neuroblastoma.
    Cohn SL; Herst CV; Maurer HS; Rosen ST
    J Clin Oncol; 1987 Sep; 5(9):1441-4. PubMed ID: 3625259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-myc oncogene amplification and prognostic factors of neuroblastoma in children.
    Nakagawara A; Ikeda K; Tsuda T; Higashi K
    J Pediatr Surg; 1987 Oct; 22(10):895-8. PubMed ID: 3316592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
    Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
    J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of N-myc oncogene amplification and S-100 protein positivity in children with neuroblastic tumors.
    Hachitanda Y; Nakagawara A; Nagoshi M; Tsuneyoshi M
    Acta Pathol Jpn; 1992 Sep; 42(9):639-44. PubMed ID: 1476058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
    Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
    Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [N-myc oncogene amplification in tumors of the sympathetic nervous system: preliminary study of methods and clinico-pathologic correlations].
    Dahbiová R; Kodet R; Soukup J; Kavan P; Smelhaus V; Koutecký J
    Cesk Patol; 1997 Aug; 33(3):83-8. PubMed ID: 9471397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.
    Nakagawara A; Arima-Nakagawara M; Scavarda NJ; Azar CG; Cantor AB; Brodeur GM
    N Engl J Med; 1993 Mar; 328(12):847-54. PubMed ID: 8441429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of oncogene activation in human neuroblastomas.
    Brodeur GM; Seeger RC; Sather H; Dalton A; Siegel SE; Wong KY; Hammond D
    Cancer; 1986 Jul; 58(2 Suppl):541-5. PubMed ID: 3719548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification and expression of the N-myc gene in neuroblastoma.
    Bartram CR; Berthold F
    Eur J Pediatr; 1987 Mar; 146(2):162-5. PubMed ID: 3569354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
    Seeger RC; Brodeur GM; Sather H; Dalton A; Siegel SE; Wong KY; Hammond D
    N Engl J Med; 1985 Oct; 313(18):1111-6. PubMed ID: 4047115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-myc oncogene and stage IV-S neuroblastoma. Preliminary observations on ten cases.
    Nakagawara A; Sasazuki T; Akiyama H; Kawakami K; Kuwano A; Yokoyama T; Kume K
    Cancer; 1990 May; 65(9):1960-7. PubMed ID: 2196987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas.
    Tsuda T; Obara M; Hirano H; Gotoh S; Kubomura S; Higashi K; Kuroiwa A; Nakagawara A; Nagahara N; Shimizu K
    Cancer; 1987 Aug; 60(4):820-6. PubMed ID: 3594401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage IVS neuroblastoma: a clinical, histological, and biological analysis of 45 cases.
    Hachitanda Y; Hata J
    Hum Pathol; 1996 Nov; 27(11):1135-8. PubMed ID: 8912820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
    Martinsson T; Sjöberg RM; Hedborg F; Kogner P
    Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome.
    Grady-Leopardi EF; Schwab M; Ablin AR; Rosenau W
    Cancer Res; 1986 Jun; 46(6):3196-9. PubMed ID: 2421891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.
    Nakagawara A; Kadomatsu K; Sato S; Kohno K; Takano H; Akazawa K; Nose Y; Kuwano M
    Cancer Res; 1990 May; 50(10):3043-7. PubMed ID: 2185879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.